Desentum
  • Home
  • Technology
  • Company
  • News
  • Contact
  • Suomi
Select Page

Desentum raised 12 million euros for advancing allergy vaccine development

by raikeeoy | Feb 8, 2024 | News

Desentum, a Finnish biopharmaceutical company with its birch pollen allergy vaccine candidate DM-101PX currently being tested in a clinical study in Canada, raised 12 M€ in a funding round arranged by an investment service company Springvest Oyj. Desentum intends to...

Desentum announces full recruitment of a clinical study of DM-101PX, an immunotherapeutic vaccine against birch pollen allergy

by kapu@raikee.fi | Nov 27, 2023 | News

Desentum announces today that DM-101-C-002, a clinical study evaluating safety and tolerability of the investigational birch pollen allergy vaccine DM-101PX, has been fully recruited and the dosing of all cohorts has been started. DM-101-C-002 is a randomised,...

First subjects dosed in a clinical study of DM-101PX, an immunotherapeutic vaccine against birch pollen allergy

by kapu@raikee.fi | Oct 13, 2023 | News

Desentum today announces the dosing of first subjects in a clinical study evaluating safety and tolerability of its investigational birch pollen allergy vaccine DM-101PX. The study, which is conducted in Canada, also assesses the effect of DM-101PX on allergic...

Desentum received clinical trial approval from Health Canada

by kapu@raikee.fi | Sep 14, 2023 | News

The Canadian regulatory authority Health Canada has approved Desentum’s clinical trial application for a clinical study on DM-101PX, an investigational preparation intended for immunotherapeutic treatment of birch pollen allergy. The planned study will test three...
Desentum raised 8 M€ to advance clinical development of lead allergy vaccine candidate

Desentum raised 8 M€ to advance clinical development of lead allergy vaccine candidate

by aisla@raikee.fi | Jan 21, 2022 | News

Desentum Oy completed a First-in-Human clinical study last year with an immunotherapeutic hypoallergen targeted for treating birch pollen allergy. In January 2022, the company raised 8 million euros in a funding round arranged by Springvest Oyj. Desentum intends to...
Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults

Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults

by aisla@raikee.fi | Oct 25, 2021 | News

Today, Desentum announced positive First-in-Human clinical data of DM-101, its lead candidate for treatment of birch pollen allergy. DM-101 was found to be safe and well tolerated in a dose regimen of 5 ascending doses, and immunological marker results indicated a...
« Older Entries
Next Entries »

Viimeisimmät artikkelit

  • Desentum’s UPSIT study with birch pollen allergy treatment DM-101PX approved by Paul-Ehrlich-Institut in Germany
  • Desentum raises €28 million to develop safer, more effective allergen immunotherapy
  • New peer-reviewed publication on Desentum’s investigational birch pollen allergen immunotherapy DM-101PX
  • Desentum to present at the 2026 EAACI annual congress in Istanbul this week
  • Desentum’s 18 M€ share issue from private investors and family offices breaks a record for unlisted growth companies in Finland

Viimeisimmät kommentit

No comments to show.

DESENTUM OY

Tekniikantie 14, 02150 Espoo, Finland
info@desentum.fi

  • Follow
  • Follow

© Desentum Oy

Privacy policy
​​Cookie settings
Website: Räikee Oy

© Desentum Oy

Tietosuojaseloste
​​Evästeasetukset
Nettisivut: Räikee Oy